PURPOSE: Genetic polymorphisms in cytochrome P450 (CYP) enzyme CYP2D6 have a substantial effect on the success of pharmacotherapy. Different models, including a predicted-phenotype model and a semi-quantitative gene dose (SGD) model, have been developed based on CYP genotype. The objective of this study was to investigate the surplus value of the SGD model in predicting the metabolic ratios (MRs) of the psychotropics venlafaxine, fluoxetine and risperidone. METHODS: Phenotype prediction and semi-quantitative gene doses were conducted after genotyping for CYP2D6 *3, *4, *5, *6, *9, *10, *41 and gene multiplication. RESULTS: The predicted-phenotype and SGD model showed increasing mean MRs with increasing predicted metabolic activity and decreasing SGD values, respectively, for all three psychotropics. The reliability of MR prediction was higher for the SGD model. CONCLUSIONS: Both models are suitable for venlafaxine, fluoxetine and risperidone. In this study, a surplus value of semi-quantitative gene dose model was present, but small, for all three psychotropics.
PURPOSE: Genetic polymorphisms in cytochrome P450 (CYP) enzyme CYP2D6 have a substantial effect on the success of pharmacotherapy. Different models, including a predicted-phenotype model and a semi-quantitative gene dose (SGD) model, have been developed based on CYP genotype. The objective of this study was to investigate the surplus value of the SGD model in predicting the metabolic ratios (MRs) of the psychotropics venlafaxine, fluoxetine and risperidone. METHODS: Phenotype prediction and semi-quantitative gene doses were conducted after genotyping for CYP2D6 *3, *4, *5, *6, *9, *10, *41 and gene multiplication. RESULTS: The predicted-phenotype and SGD model showed increasing mean MRs with increasing predicted metabolic activity and decreasing SGD values, respectively, for all three psychotropics. The reliability of MR prediction was higher for the SGD model. CONCLUSIONS: Both models are suitable for venlafaxine, fluoxetine and risperidone. In this study, a surplus value of semi-quantitative gene dose model was present, but small, for all three psychotropics.
Authors: J Kirchheiner; K Brøsen; M L Dahl; L F Gram; S Kasper; I Roots; F Sjöqvist; E Spina; J Brockmöller Journal: Acta Psychiatr Scand Date: 2001-09 Impact factor: 6.392
Authors: Jenny E Kootstra-Ros; Marga J M Van Weelden; John W J Hinrichs; Peter A G M De Smet; Jan van der Weide Journal: J Clin Pharmacol Date: 2006-11 Impact factor: 3.126
Authors: S M Fogelman; J Schmider; K Venkatakrishnan; L L von Moltke; J S Harmatz; R I Shader; D J Greenblatt Journal: Neuropsychopharmacology Date: 1999-05 Impact factor: 7.853
Authors: Werner Steimer; Konstanze Zöpf; Silvia von Amelunxen; Herbert Pfeiffer; Julia Bachofer; Johannes Popp; Barbara Messner; Werner Kissling; Stefan Leucht Journal: Clin Chem Date: 2004-06-17 Impact factor: 8.327
Authors: David Villagra; John Goethe; Harold I Schwartz; Bonnie Szarek; Mohan Kocherla; Krystyna Gorowski; Andreas Windemuth; Gualberto Ruaño Journal: Biomark Med Date: 2011-08 Impact factor: 2.851
Authors: Gualberto Ruaño; Bonnie L Szarek; David Villagra; Krystyna Gorowski; Mohan Kocherla; Richard L Seip; John W Goethe; Harold I Schwartz Journal: Biomark Med Date: 2013-06 Impact factor: 2.851